Clinical Trial Update: A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide

View source ↗

Summary

The document is a clinical trial update for a study evaluating androgen deprivation therapy plus apalutamide or enzalutamide in metastatic hormone-sensitive pro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-sensitive Prostate Cancer

Drugs mentioned

• ERLEADA (apalutamide)
• Xtandi (enzalutamide)

Snippet

Sponsor: Janssen-Cilag Ltd. | Conditions: Metastatic Hormone-sensitive Prostate Cancer | Status: ACTIVE_NOT_RECRUITING